title: Diagnosis of pre-disseminated intravascular coagulation stage with hemostatic molecular markers. The Mie DIC Study Group.
abstract: We examined various hemostatic abnormalities in 395 patients with disseminated intravascular coagulation (DIC), in 177 patients in a Pre-DIC stage, and in 99 patients who did not exhibit DIC. Pre-DIC was defined as the condition at least one week before the onset of DIC. The differences in activated partial thromboplastin time (APTT), FDP, prothrombin time (PT) ratio, fibrinogen, and platelet count between DIC and Non-DIC patients were significant, but there were no significant differences in these parameters between Pre-DIC and Non-DIC patients. Plasma levels of fibrin-D-dimer, thrombin-antithrombin complex (TAT), plasmin-plasmin inhibitor complex (PPIC), soluble fibrin monomer (sFM), prothrombin activated peptide F1 + 2 (F1 + 2), thrombomodulin (TM), tissue type plasminogen activator (t-PA), and PA inhibitor (PAI-I) in DIC patients were significantly higher than levels in Non-DIC patients. However, only TAT, sFM and PAI-I values in the Pre-DIC patients were significantly higher than the values in the Non-DIC patients. Almost all the hemostatic molecular markers examined had high sensitivity for DIC, but only TAT and PPIC had high sensitivity for Pre-DIC. Specificity for DIC was also high with TAT, sFM, and F1 + 2. Early diagnosis and early treatment are important in DIC; we believe that it is possible to predict Pre-DIC by assessing values for the combination of hemostatic molecular markers.
authors.affiliation: 2nd Department of Internal Medicine, Mie University School of Medicine, Japan.
authors.forename: H
authors.initials: H
authors.lastname: Wada
authors.forename: Y
authors.initials: Y
authors.lastname: Wakita
authors.forename: T
authors.initials: T
authors.lastname: Nakase
authors.forename: M
authors.initials: M
authors.lastname: Shimura
authors.forename: K
authors.initials: K
authors.lastname: Hiyoyama
authors.forename: S
authors.initials: S
authors.lastname: Nagaya
authors.forename: Y
authors.initials: Y
authors.lastname: Mori
authors.forename: K
authors.initials: K
authors.lastname: Deguchi
authors.forename: H
authors.initials: H
authors.lastname: Shiku
mesh_terms: D000990:Antithrombin III / Q000378:metabolism; D015415:Biomarkers / Q000097:blood*; D004211:Disseminated Intravascular Coagulation / Q000097:blood / Q000175:diagnosis*; D005337:Fibrin / Q000378:metabolism; D005338:Fibrin Fibrinogen Degradation Products / Q000378:metabolism; D005340:Fibrinogen / Q000378:metabolism; D005341:Fibrinolysin / Q000037:antagonists & inhibitors / Q000378:metabolism; D006801:Humans; D010314:Partial Thromboplastin Time; D010447:Peptide Hydrolases / Q000378:metabolism; D010976:Platelet Count; D011517:Prothrombin Time
chemical_list: D015415:Biomarkers; D005338:Fibrin Fibrinogen Degradation Products; C046193:antithrombin III-protease complex; D000990:Antithrombin III; D005337:Fibrin; D005340:Fibrinogen; D010447:Peptide Hydrolases; D005341:Fibrinolysin